J. Trappe

发表

Characterization of the Novel and Specific PI3Kα Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014, Molecular Cancer Therapeutics.

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor.

D. Fabbro, W. Jahnke, G. Rummel, 2015, ACS medicinal chemistry letters.

Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805

D. Erdmann, J. Brueggen, P. Furet, 2010, Molecular Cancer Therapeutics.

Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo.

J. Trappe, S. Goldmann, K. Henninger, 2001, Antiviral research.

Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors.

J. Bajorath, S. Laufer, M. González-Medina, 2019, European journal of medicinal chemistry.

Identification and optimisation of a 4',5-bisthiazole series of selective phosphatidylinositol-3 kinase alpha inhibitors.

P. Furet, G. Caravatti, T. Zoller, 2015, Bioorganic & medicinal chemistry letters.

Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action.

J. Trappe, J. Herrington, S. Goldmann, 2001, The Journal of antimicrobial chemotherapy.

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

Audrey Kauffmann, Jianjun Yu, Yumin Dai, 2014, Clinical Cancer Research.

Original articles Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action

J. Trappe, J. Herrington, S. Goldmann, 2001 .

Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.

W. Jahnke, P. Couttet, N. Ostermann, 2020, Journal of medicinal chemistry.

Targeting Plasmodium phosphatidylinositol 4-kinase to eliminate malaria

K. Kuhen, E. Winzeler, S. Meister, 2013, Nature.

The Substrate-Activity-Screening methodology applied to receptor tyrosine kinases: a proof-of-concept study.

D. Fabbro, D. Seebach, H. Moebitz, 2012, European journal of medicinal chemistry.

Substrate profiling of IGF-1R and InsR: identification of a potent pentamer substrate.

D. Fabbro, D. Seebach, H. Moebitz, 2011, Bioorganic & medicinal chemistry letters.

Small Molecule Therapeutics Characterization of the Novel and Speci fi c PI 3 K a Inhibitor NVP-BYL 719 and Development of the Patient Strati fi cation Strategy for Clinical Trials

D. Erdmann, J. Lehár, W. Sellers, 2014 .

Targeting Plasmodium PI(4)K to eliminate malaria

Robert W. Sauerwein, Bruce Russell, David C. Tully, 2013, Nature.

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

M. Lindvall, A. Kauffmann, C. Fanton, 2014, Clinical Cancer Research.